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Introduction
Renal cell carcinoma (RCC) accounts for approximately 2-3% of all malignant diseases in adults [1] . A feature of this malignancy is potential venous tumour thrombus (VTT) formation. At presentation, 4-10% of RCC patients have thrombus in the renal vein or inferior vena cava (IVC) [2] . The treatment of choice for RCC with VTT remains radical nephrectomy with thrombectomy [3] . Aggressive surgical resection is widely accepted as the default management option for these patients [4] [5] [6] [7] .
There is variation in how the surgery is undertaken in terms of preoperative strategies (eg, use of IVC filter [8] or embolisation of tumour [9] ), surgical approach to access the IVC, special manoeuvres (eg, liver mobilisation, milking of thrombus, aortic cross-clamping, or Pringle's manoeuvre), circulatory bypass procedures to achieve vascular control (eg, venovenous bypass or cardiopulmonary bypass [CPB] and deep hypothermic circulatory arrest [DHCA] [10] ), and perioperative strategies (eg, anticoagulation). In general, the IVC tumour is approached according to the VTT level [11, 12] .
Although several reviews regarding the management of vena caval thrombus (VCT) in nonmetastatic RCC have been published [13] [14] [15] [16] , most were narrative reviews using nonstandardised methodology. The primary objective of this systematic review was to determine the comparative effectiveness and harms of the different surgical therapies in treating patients with VCT from nonmetastatic RCC and to identify knowledge gaps.
2.
Evidence acquisition
Search strategy
The review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [17] and Cochrane review principles [18] and was undertaken as part of the European Association of Urology (EAU) RCC guideline panel's forthcoming 2016 guideline update exercise. Highly sensitive electronic searches were undertaken to identify published and ongoing comparative studies and case series of surgical management of RCC with VCT. Searches were limited to studies published from the year 2000 onwards to reflect current clinical practice. No language restrictions were imposed. Searches conducted in bibliographical databases were complemented by additional sources, including the reference lists of included studies, which were hand searched to identify additional relevant studies, and reports identified by the guideline panel.
The databases searched were Medline, Medline InProcess, Embase, the Cochrane Controlled Trials Register, the Science Citation Index, and the Conference Proceedings Citation Index. Systematic reviews and other background information were identified by searching the Cochrane Database of Systematic Reviews. In addition, ClinicalTrials. gov and the World Health Organisation International Clinical Trials Registry were searched to identify ongoing trials. Full details of the search strategies used are described in Appendix 1.
Two reviewers screened all abstracts and full-text articles independently. Disagreement was resolved by discussion or reference to an independent third party.
Types of study design included
Randomised controlled trials (RCTs), quasi-RCTs, nonrandomised comparative studies (NRCSs), and single-arm case series (with at least 50 patients) were eligible for inclusion.
Types of participants included
The study population was composed of patients diagnosed with nonmetastatic RCC with tumour extension into the IVC. Studies in which metastatic disease accounted for >10% of their participants were excluded. Previous surgery for VCT, recurrent tumours, and non-RCC malignancies were also grounds for exclusion.
Types of interventions included
Studies reporting any kind of surgery for VCT in at least one arm were included. For comparative studies, eligible comparators were either no intervention or any alternative surgery or treatment. Perioperative strategies were also included as long as thrombectomy was included in one arm.
Types of outcome measures included
The main outcome measures were specified a priori and included overall survival (OS) and cancer-specific survival (CSS). Other oncologic outcomes included incidence of recurrence, recurrence-free survival (RFS), and incidence of metastatic disease. Additional outcome measures included 
complications (including mortality), perioperative and recovery outcomes (eg, length of hospital stay, blood loss), and quality of life.
Assessment of risk of bias and confounding
For RCTs, risk of bias (RoB) assessment was undertaken using the Cochrane Collaboration RoB tool. For NRCSs, a modified RoB tool was adapted for use [19] . In addition, for NRCSs, the main confounders were identified a priori by the guideline panel for the primary outcome. A study was considered to be at high RoB if any of the confounders were imbalanced. The main confounders identified included age, tumour level, and presence of metastasis. Each confounder was assessed according to whether it had been considered by the authors (yes or no), whether the confounder was balanced across the groups (high risk, low risk, or unclear), and the degree to which adjustment had been made for the confounder (high risk, low risk, or unclear). Based on the available methodological research in the literature [20, 21] , RoB in the eligible case series reports was assessed according to four parameters:
Selection bias (did study cohort include consecutive patients?) Attrition bias (were patients lost to follow-up accounted for?) Detection bias (were primary outcomes appropriately measured?) Use of a priori protocol
Data analysis
A data extraction form was developed a priori to collect information on study design, participant characteristics, characteristics of interventions, and outcome measures. Two reviewers independently extracted data relating to the prespecified outcomes. For data analysis, descriptive statistics were used to summarise baseline characteristic data. The main results were presented in a summary-offindings table. Quantitative synthesis (meta-analysis) was planned only for RCTs. For all other studies, a narrative synthesis of the evidence was planned.
Evidence synthesis
3.1.
Quantity of evidence identified
The literature searches identified 824 articles (Fig. 1 ). Of these, 71 were selected for full-text screening. Ten comparative studies [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] and four case series [7, [32] [33] [34] were included.
Characteristics of the included studies
Data were included for 2262 patients from 14 studies (15 reports), all of which were retrospective studies (Table 1) . No RCTs or prospective NRCSs were identified. Consequently, data were summarised narratively. Table 2 summarises the outcome results for all 10 comparative studies [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] .
3.4.1.1. Minimal access versus traditional median sternotomy. Two studies [23, 29] compared minimal access (MA) techniques with traditional median sternotomy (TMS), but data were too heterogeneous for data pooling. In both studies, the median operating time was significantly shorter with MA techniques than with TMS. The MA group had numerically longer but not statistically significant RFS [23] and OS [29] [ ( F i g .
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than the TMS group. The study by Wotkowicz et al [29] was conducted in patients with T3 and T4 RCC, whereas Faust et al [23] did not report primary tumour stage. Faust et al [23] also found statistically significant differences in favour of MA for wound infection, sepsis, hospital stay, and ventilatory requirements. Similarly, Wotkowicz et al [29] found statistically significant differences in favour of MA for transfusion, hospital stay, and ventilator requirements.
3.4.1.2. Preoperative renal artery embolisation versus no preoperative renal artery embolisation. Chan et al [22] compared preoperative renal artery embolisation (PRAE) with no PRAE in patients with T3 RCC and found that PRAE was associated with increases in operating time, blood loss, and hospital stay (all statistically significant) and higher perioperative mortality (8.4% vs 3.4% for PRAE vs no PRAE respectively, p value not stated). PRAE, however, appeared to be associated with a nonsignificant trend towards a lower risk of death from any cause. Tang et al [28] found that PRAE may be more appropriate for patients with advanced tumour thrombus because of its benefit in reducing intraoperative blood loss and blood transfusion (p = 0.043 and p = 0.028, respectively), but otherwise the authors did not find a measurable advantage in terms of long-term prognosis for patients in the PRAE group.
Cardiopulmonary bypass versus no cardiopulmonary
bypass. Nguyen et al [26] compared 455 patients with level III-IV thrombus who underwent nephrectomy and IVC thrombectomy with and without CPB. OS did not differ significantly between both groups (p = 0.18). Orihashi et al [27] compared three interventions (single caval clamp without circulatory support, partial bypass, and circulatory arrest) for patients with level I-IV thrombus. They found no significant differences in operative deaths, 5-yr OS, local recurrence, blood loss, or blood transfusion requirements. Finally, in the study by Krishnamurthi et al [25] , CPB was associated with significantly less bypass time (p < 0.001) and total operative time (p = 0.004) compared with DHCA for patients with thrombus extending to the right atrium. Fewer major complications were reported with CPB, although the differences were not statistically significant (p = 0.17).
[ [ [7, [32] [33] [34] evaluated the surgical management of RCC with VCT. Kulkarni et al [34] reported that 5-yr OS and disease-free survival (DFS) were 63% and 55%, respectively. The authors also noted that pathologic factors such as stage and grade of tumour, rather than clinical factors such as level of thrombus, influenced survival, confirming another study [7] that reported that cephalad extension of tumour thrombus does not affect CSS (p = 0.4874 for 5-and 10-yr CSS). Al Otaibi et al [32] reported that 5-yr OS and DFS were 47% and 35%, respectively, and suggested that although the level of the thrombus might affect the recurrence rate, it had no impact on OS. Finally, in another study with 640 patients [33] , patients with higher levels of VTT were more likely to experience early complications (p < 0.001), but there was no statistically significant difference in late complications.
Discussion
Principal findings
The main objective of the review was to synthesise evidence regarding the benefits of the different surgical techniques in treating VCT from nonmetastatic RCC. Eligible studies mainly reported on preoperative strategies, surgical access, and circulatory bypass procedures; apart from four case series, no comparative studies assessed the benefits or harms of surgical excision of VCT. In terms of surgical access, MA techniques appeared to have better perioperative and recovery outcomes than TMS, but it is not known if these differences are important oncologically. In addition, whether IVC thrombectomy is performed simultaneously with the kidney removal (en bloc) or after it does not appear to influence perioperative outcomes [24] ; however, there was clinical heterogeneity between the groups, with the thrombus level and clinical stage lower in the en bloc group.
In considering data on circulatory bypass procedures, one study [27] found no significant difference in outcomes between CPB with DHCA or partial bypass under normothermia or single caval clamp without circulatory support; however, results from this study should be interpreted with caution due to clinical heterogeneity. CPB with DHCA was performed in patients with significantly higher levels of tumour extension, introducing a high risk of indication bias. When the effect of use of CPB was evaluated in patients with level III-IV tumour thrombus, it did not significantly affect CSS or OS [26] , and in patients with thrombus extending to the right atrium, CPB resulted in improved perioperative outcomes compared with DHCA [25] .
Regarding PRAE, data from two studies [22, 28] showed that it had no oncologic benefits and resulted in significantly worse perioperative and recovery outcomes, including possibly higher perioperative mortality shown in one study [22] . In the study by Tang et al [28] , however, PRAE demonstrated a benefit for patients with advanced tumour thrombus (above the hepatic vein) in reducing intraoperative blood loss and blood transfusion. These results coincide with those of a previous study [36] that found no measurable advantage with PRAE in patients with nonmetastatic and metastatic RCC with VCT, but PRAE was associated with increased complications. Consequently, the available data suggest that PRAE does not appear to have an adjunct role prior to surgery, although it might be considered for patients with advanced tumour thrombus.
With regard to the use of an IVC filter in reducing IPE, the findings from one study [30] -available only as an abstract and involving cohorts from different time periods-are of doubtful clinical and statistical significance. Moreover, in 8% of patients in the IVC filter group, the filter could not be removed from the sheath because of tumour thrombus incorporation requiring intervention with cavotomy to extract the filter. For this reason, other authors have recommended avoiding the insertion of IVC filters [8, 15, 16] . Conversely, another study [31] suggested that temporary IVC filter placement is a feasible method of avoiding tumour thrombus embolism. These results have unclear clinical and statistical significance because no data are available for the control cohort, and in the experimental cohort, a different surgical technique for IVC thrombectomy was used. In summary, there was no strong evidence to support the use of IVC filters, although data from better designed prospective studies would be required to either confirm or refute this assertion.
Last, data from several large case series (n > 50 patients) concerning surgical management of RCC with VCT suggest that surgical treatment can be associated with meaningful oncologic benefits, although it is technically complex and challenging; however, the quality of the evidence was poor. This systematic review revealed several important knowledge gaps in the evidence base. We were unable to identify any high-quality evidence that addresses the question of whether patients with nonmetastatic RCC and VCT derive a benefit from surgery to remove the thrombus and how thrombectomy influences prognosis from an oncologic perspective. Currently, aggressive surgical treatment is acknowledged as the only potentially curative treatment [2, 3, 10, 37] , provided that complete tumour thrombus removal can be achieved [38, 39] . The justification for such an approach is based on relatively low levels of evidence; single-arm case series of patients who underwent surgery for VCT often showed comparable survival outcomes with corresponding TNM-stage patients without VCT. In a matched-pair analysis of patients with RCC and VCT and patients with RCC without VCT, Kuczyk et al [40] concluded that a radical surgical approach is essential as standard therapy for the treatment of patients with RCC and VCT.
Nevertheless, in the absence of any reliable comparative data, it remains unclear to what extent surgical treatment of VCT influences prognosis. In addition, there appear to be contradictory data regarding the extent of thrombus removal, with some studies showing that complete removal of IVC tumour thrombus did not affect patient prognosis [7, 37] . These conflicting data demonstrate the need for better quality prospective studies involving different tumour stages, appropriate stratification of patients based on relevant confounding factors, and various surgical approaches with long-term follow-up to answer these questions more definitively. No eligible study addressed this question. The prognostic value of IVC involvement has been a controversial topic, and although it has been extensively evaluated, there is still a considerable degree of uncertainty. In many studies, there is little or no correlation between the level of tumour thrombus within the IVC and OS or DSS [7, 11, [41] [42] [43] , whereas other studies identified IVC thrombus as a negative prognostic factor [5, 31, 37, 44, 45] . In the context of nonmetastatic disease with isolated VTT, the 5-yr CSS ranged between 18% and 68% after surgical resection [2, 4] . Although surgery for IVC tumour thrombus can be curative in many patients, a large proportion of patients develop recurrence and progressive disease [6, 32] . In this regard, a prognostication system that combines the various independent prognostic factors, such as the University of California Los Angeles Integrated Staging System [46] , may better predict the outcomes following surgery and thereby facilitate patient selection for surgery. The objectives of surgery include complete resection of the primary tumour and VTT while averting tumour embolism, maintaining haemodynamic stability, minimising blood loss, and circumventing organ ischaemia. Data from included studies suggest that the surgical method appears to be dependent on the level of the tumour thrombus and the grade of occlusion of the IVC [23, 27, 29, 32, 34] ; however, the question of which approach is best for each thrombus level was not appropriately addressed by any of the included studies.
Based on conventional wisdom and traditional dicta, for level I tumour thrombus, minimal modifications of the standard surgical approach are usually required [11] . Level II thrombus can be managed with occlusion of the IVC below and above the thrombus in the IVC and the contralateral renal vein including occlusion of lumbar veins entering the IVC and can generally be resected without bypass [11] . For level III thrombus, the surgery is more demanding, with more complex dissections of IVC and the liver. For level IV thrombus, the optimal management is still debatable; traditionally, CPB with or without DHCA has been used in those patients [47, 48] but seems to be associated with a high risk of blood loss, coagulopathy, and longer operating times [39, 49] . In our review, however, one study [26] found no evidence that CPB was associated with higher surgical complications or longer hospital stay and concluded that, from an oncologic perspective, use of CPB is safe for the treatment of patients with RCC and level III-IV tumour thrombus. Studies suggesting that non-CPB approaches are feasible [39, [50] [51] [52] have also been reported. Venovenous bypass is another alternative method that has been used in selected cases and has been associated with decreased intraoperative blood loss and operating times compared with CPB [53] .
In summary, although data representing low levels of evidence exist, it must be acknowledged that due to the paucity of comparative data, the relative benefits and harms of these different techniques and approaches and how they vary according to different thrombus levels remain unclear.
Strengths and limitations of the review
The strengths of this review are the systematic, transparent, and robust approach taken to examine the evidence base; the use of Cochrane review methodology throughout, including the assessment of RoB and confounding, which are essential to any review involving NRCSs and case series; and adherence to PRISMA guidelines. The search strategy was complemented by additional sources for potentially important articles, including an expert panel (EAU RCC guideline panel) because the work was undertaken as part of the panel's guideline update for 2016. This approach ensured a comprehensive review of the literature while maintaining methodological rigour and enabled the authors to put into clinical context the relevance and implications of the review findings.
The major limitation of this review is that all studies were retrospective and had high risks of bias and confounding. This review highlights the lack of high-quality and reliable evidence for the management of VCT in patients with nonmetastatic RCC. The EAU has issued some guidance on the management of patients with RCC and VCT, based on the present systematic review findings [54] .
A host of literature surrounds surgical techniques relating to the resection of RCC with VCT, but the vast majority of published reviews are narrative in nature and use unspecified or nonstandardised methodology. In a narrative review article by Pouliot et al [15] , the authors reviewed a multitude of aspects, including surgical treatment options, to create an algorithm for deciding on the type of surgical treatment for VCT. One of their conclusions suggested that PRAE should be used only as a palliative procedure in poor surgical candidates or when the renal hilum is full of disease. The authors also advised against preoperative IVC filters except in cases in which the IVC is completely and chronically occluded.
Woodruff et al [16] established a multidisciplinary perioperative protocol for patients with RCC and VCT. One of their conclusions was that such patients should not be offered IVC filters as much as possible because there is the potential for caval thrombosis, which can make surgical resection more challenging. These conclusions are similar to those of Lawindy et al [13] , who also did not support preoperative IVC placement. In addition, Lawindy et al suggested that the surgical approach should be tailored to the individual patient as well as the level of the IVC tumour thrombus. Based on a narrative review, Margulis et al [14] recommended that routine renal artery embolisation prior to radical nephrectomy should not be advocated.
Recently, the results of the International Renal Cell Carcinoma-Venous Thrombus Consortium [45] were published. The authors concluded that tumour thrombus level is an independent survival predictive factor and that for patients with level III-IV tumour thrombus, surgical treatments with or without CPB are equally effective oncologically. There was no reliable conclusion about the role of PRAE.
Conclusions
The surgical management of patients with nonmetastatic RCC and VCT is complex, yet complete surgical resection appears to be the only potentially curative intervention. This systematic review set out to determine the evidence base with regard to the comparative effectiveness and harms of the multitude of surgical techniques and approaches in dealing with this condition. Traditional surgical dicta concerning the management of VCT indicate that patients with nonmetastatic RCC and VCT and acceptable performance status should be considered for surgical intervention, regardless of VCT level. Although the most appropriate or efficacious surgical technique remains unclear, it should be selected judiciously for each case based on the level of tumour thrombus. The review findings reveal an evidence base derived from retrospective studies and case series with significant risks of bias and confounding, and there was a serious lack of prospective comparative studies. Future research must endeavour to carefully design prospective comparative studies with experimental designs and use of appropriate controls to ascertain which surgical technique offers the best outcomes. Even in the absence of RCTs, the field can benefit from well-designed, prospective NRCSs based on sound methodological principles [55] . Until then, it seems prudent to make treatment decisions on a case-by-case basis, relying on a combination of likely prognostic variables within the context of a multidisciplinary team. Statistical analysis: Lardas, Lam.
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